Previous Article | Next Article 
Journal of Virology, April 1999, p. 3430-3437, Vol. 73, No. 4
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
The Equine Herpesvirus 1 US2 Homolog Encodes a
Nonessential Membrane-Associated Virion Component
Alexandra
Meindl1,2 and
Nikolaus
Osterrieder1,*
Institute of Molecular and Cellular Virology,
Friedrich-Loeffler-Institutes, Federal Research Center for Virus
Diseases of Animals, D-17498 Insel Riems,1 and
Institute for Medical Microbiology, Infectious and Epidemic
Diseases, Ludwig-Maximilians-University, D-80539
Munich,2 Germany
Received 26 October 1998/Accepted 23 December 1998
 |
ABSTRACT |
Experiments were conducted to analyze the equine herpesvirus 1 (EHV-1) gene 68 product which is encoded by the EHV-1 US2
homolog. An antiserum directed against the amino-terminal 206 amino
acids of the EHV-1 US2 protein specifically detected a
protein with an Mr of 34,000 in cells infected
with EHV-1 strain RacL11. EHV-1 strain Ab4 encodes a
44,000-Mr Us2 protein, whereas
vaccine strain RacH, a high-passage derivative of RacL11, encodes a
31,000-Mr Us2 polypeptide.
Irrespective of its size, the US2 protein was incorporated
into virions. The EHV-1 US2 protein localized to membrane
and nuclear fractions of RacL11-infected cells and to the envelope
fraction of purified virions. To monitor intracellular trafficking of
the protein, the green fluorescent protein (GFP) was fused to the
carboxy terminus of the EHV-1 US2 protein or to a truncated
US2 protein lacking a stretch of 16 hydrophobic amino acids
at the extreme amino terminus. Both fusion proteins were detected at
the plasma membrane and accumulated in the vicinity of nuclei of
transfected cells. However, trafficking of either GFP fusion protein
through the secretory pathway could not be demonstrated, and the EHV-1
US2 protein lacked detectable N- and O-linked
carbohydrates. Consistent with the presence of the US2 protein in the viral envelope and plasma membrane of infected cells, a US2-negative RacL11 mutant (L11
US2)
exhibited delayed penetration kinetics and produced smaller
plaques compared with either wild-type RacL11 or a
US2-repaired virus. After infection of BALB/c mice with
L11
US2, reduced pathogenicity compared with the parental
RacL11 virus and the repaired virus was observed. It is concluded that
the EHV-1 US2 protein modulates virus entry and
cell-to-cell spread and appears to support sustained EHV-1 replication
in vivo.
 |
TEXT |
Equine herpesvirus type 1 (EHV-1), a
member of the family Alphaherpesvirinae, causes late-time
abortions, respiratory disease, and neurological disorders in equines
(1). EHV-1 possesses a type D herpesvirus genome which is
composed of a unique long (UL) region and a unique short
(US) region, the latter being bracketed by two inverted
repeat regions (IRS and IRT) (16,
47). Comparison of the nucleotide sequences of the
US-IRS region of strains Ab4p, KyA, and RacL11
and attenuated modified live vaccine (MLV) strain RacH revealed some
genomic variation, and a 0.85-kbp deletion affecting genes 67 and 68 of
RacH (the IR6 gene and the US2 homolog) was identified
(5, 19, 32, 43). The unique IR6 protein has been shown to
form rod-like structures in infected cells, and ability to form these
structures is correlated with the virulence of EHV-1 Rac strains
(32-34).
EHV-1 gene 68 is the homolog of the US2 gene of herpes
simplex virus type 1 (HSV-1) (5, 11, 26). According to
nucleotide sequences and the deduced amino acid sequences, EHV-1
strain Ab4p would encode a 47,000-Mr
Us2 protein, whereas wild-type strain RacL11 would encode a
34,000-Mr US2 protein. This
difference in Mr is caused by a frameshift
mutation in strain Ab4p at position 125,540 (43) compared to
RacL11 (19).
US2 homologs have been described in various members
of the subfamily Alphaherpesvirinae, e.g., in HSV-2
(13), bovine herpesvirus 1 (24), canine
herpesvirus (15), EHV-4 (42), and pseudorabies virus (PrV) (38, 44), as well as in the avian
members of the subfamily, i.e., Marek's disease virus (MDV)
(7, 8, 40), herpesvirus of turkeys (49), and
infectious laryngotracheitis virus (48). In contrast,
varicella-zoster virus does not encode a US2 homolog
(12). Analyses of a
US2-US3-negative HSV-1 mutant showed that
deletion of the respective genes resulted in an attenuated phenotype in
a mouse infection model (27). In addition, a
US2-negative HSV-1 mutant exhibited a small-plaque
phenotype and grew to slightly reduced titers after infection of cells
at a low multiplicity of infection (MOI) compared with the wild-type
virus (46). The Bartha and Norden strains of PrV contain
genomic deletions that encompass the US2-homologous gene
(28K gene), yet they are able to replicate efficiently in tissue
culture and in the natural host (28, 38). A 28K-negative
mutant was not attenuated in pigs (21), but the mutant virus
exhibited delayed kinetics of penetration into cells of the nasal
mucosa (45). US2-negative MDV retained the
abilities to establish latent infection and cause oncogenic
transformation (36, 37).
The aims of this study were to characterize the US2 homolog
of EHV-1 and to analyze the function of the US2 protein for
virus replication in vitro and in vivo. This was achieved by generating a US2-specific antiserum which was used to examine the
localization of the protein in infected cells and virions. The
intracellular localization of the EHV-1 US2 protein was
further assessed by analysis of constructs of the green fluorescent
protein (GFP) fused to full-length or the amino-terminally truncated
US2 protein. Lastly, by engineering and testing of
US2-negative EHV-1, the role of the US2 gene
product in virus replication was examined.
Identification of the EHV-1 US2 protein.
Previous
studies had shown that US2-encoding sequences vary between
individual EHV-1 strains. To confirm previously published sequences of
strains Ab4p (43), RacL11 (19), RacH
(19), and KyA (5), the US2 gene
region of strains Ab4 (not plaque purified; kindly provided by
N. Edington), wild-type RacL11, MLV strain RacH, and KyA (kindly
provided by D. J. O'Callaghan) was amplified by a standard PCR
(39) using Pfu polymerase (Stratagene) and the
primers listed in Table 1. The amplified
sequences were cloned in pTZ18R (Amersham-Pharmacia) and sequenced by
cycle sequencing using fluorescent M13 primers (MWG-Biotech) and
Taq polymerase (Amersham-Pharmacia). The gene 68 (US2) sequence of strain Ab4 did not differ from that
reported for the corresponding sequence of plaque-purified isolate Ab4p
(43). Also, the reported RacL11 and KyA US2
sequences (5, 19) were confirmed. MLV strain RacH exhibited
an 853-bp deletion in the IRS-US junction. This deletion leads to a frameshift in the US2 open reading
frame (ORF) compared with the wild-type RacL11 US2
sequence, such that the carboxy-terminal 27 amino acids of the RacL11
US2 gene product are replaced with 11 missense amino acids
in strain RacH (data not shown; 19).
To specifically detect the EHV-1 US2 protein in infected
cells and purified virions, sequences encoding the amino-terminal 206 amino acids of the RacL11 US2 ORF were amplified by PCR
(Table 1) and cloned into plasmid pQE30 (Qiagen) (Fig.
1). The resulting recombinant plasmid,
pQUS2, was transformed into Escherichia coli M15
cells. The His-tagged US2 protein was overexpressed
and purified by Ni2+ affinity chromatography in
accordance with the manufacturer's instructions. After elution of the
fusion protein using imidazole, a
24,000-Mr protein could be identified by
Coomassie blue staining or Western blot analysis using the
MRGS-His antibody (Qiagen) (data not shown). The
pQUS2 protein was dialyzed against phosphate-buffered saline (PBS), emulsified in complete (first immunization) or incomplete (booster immunizations) Freund's adjuvant, and injected
intramuscularly a total of five times into a New Zealand White rabbit
(Charles River). The EHV-1 US2-specific antiserum obtained
was used to investigate US2 expression in infected-cell
lysates and purified virions by Western blotting (22, 34).
Rabbit kidney Rk13 cells were infected with EHV-1 at an MOI
of 5, and cell lysates were prepared at 2, 4, 6, 8, 10, 14, 16, or
24 h postinfection (p.i.), adjusted to equal protein
concentrations by using the BCA kit (Pierce), and separated by sodium
dodecyl sulfate-12% polyacrylamide gel electrophoresis (PAGE)
(23, 34, 41). From 8 to 24 h p.i., a
34,000-Mr protein was detected with the
anti-US2 serum in cells infected with EHV-1 strains RacL11,
RacM24, RacM36 (19, 32, 33), and KyA. Consistent with the
altered nucleotide sequences, a 44,000-Mr
US2-specific protein was detected in Ab4-infected cell lysates, and the US2 protein of MLV EHV-1 strain
RacH exhibited an apparent Mr of 31,000. In
contrast, no US2-specific reactivity was detected in lanes
containing L11
US2-infected cell proteins (Fig. 1) or in
mock-infected Rk13 cells (data not shown). Western blot
analyses using virions purified by sucrose gradient centrifugation (32) were performed to analyze whether the EHV-1
US2 protein is a structural component of virions.
US2-specific reactivity was detected in all of the virus
strains investigated, irrespective of the size of the US2
protein (Fig. 2A). However, the
electrophoretic mobilities of the US2 proteins were
slightly decreased compared with those of infected-cell lysates, and a
35,000-Mr protein was detected in RacL11 and KyA
virions, a 32,000-Mr protein was detected in
RacH virions, and a 45,000-Mr
polypeptide was detected in Ab4. No specific reaction with the
anti-US2 antibody was observed in lanes containing
L11
US2 virion proteins (Fig. 2A).

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 1.
Diagram of the recombinant plasmids and viruses used in
this study. Shown is a BamHI map of EHV-1 strain RacL11 and
a magnification of the US-IRS junction. ORFs
present at the US-IRS junction are indicated.
The IR6 gene (gene 67) is a unique gene, gene 68 represents the
US2 homolog, and gene 69 encodes the US protein
kinase (5, 31, 43). The construction of recombinant plasmids
pQUS2, pUS2-GFP, phyUS2-GFP, and
p US2 + is detailed in the text. The His
tag of pQUS2 is shown as a black box, and the
24,000-Mr pQUS2 protein was purified
by Ni2+ affinity chromatography. The enhanced GFP (EGFP)
sequences of pUS2-GFP and phyUS2-GFP are
indicated. Restriction enzyme sites are given.
|
|

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 2.
Western blot analysis of the US2 protein.
Purified virions, as well as subcellular or subviral fractions, were
separated by sodium dodecyl sulfate-12% PAGE (23),
transferred to nitrocellulose (22), and probed with the
indicated antibodies. (A) Detection of the US2 protein with
the generated US2-specific antiserum in virions purified by
sucrose gradient centrifugation. The US2-negative RacL11
virus (L11 US2) served as a negative control. (B)
Analysis of Triton X-100-treated virions. Purified RacL11 virions were
incubated with 2% Triton X-100 and subjected to ultracentrifugation.
Pellet and supernatant (Sup.) fractions were loaded onto individual
lanes of a polyacrylamide gel and analyzed with anti-US2 serum, MAb 3F6 (2), or an
anti-IR6 antibody (31). (C) Cells infected with RacL11 were
harvested at 14 h p.i., and subcellular fractionation
(4) was performed. Isolated fractions were separated and
probed with anti-US2 serum. Anti-EHV-1 gB MAb 3F6 served as
a control antibody. An unspecific 30,000-Mr band
reacting in the cytoplasmic fraction with the anti-US2
antibody is marked with a circle. Prestained molecular weight marker
(Gibco-BRL) sizes are indicated in thousands.
|
|
In a series of experiments, the putative N- or O-glycosylation of the
EHV-1 U
S2 protein was analyzed because the amino acid
sequence of the EHV-1 U
S2 protein contains two
N-glycosylation
consensus sites (
5,
19,
43). Enzymatic
deglycosylation
by using peptide-
N-glycosidase F and
endo-

-
N-acetylglucosaminidase
H (Roche Molecular
Biochemicals) or incubation of infected cells
in the presence of
tunicamycin (Roche Molecular Biochemicals)
did not result in increased
electrophoretic mobility of the U
S2
protein, whereas
increased electrophoretic mobility of EHV-1 glycoprotein
B (gB) was
readily detected in both experiments. Similarly, incubation
of purified
RacL11 virions in the presence of
O-glycosidase and
neuraminidase (Roche Molecular Biochemicals) did not result in
alteration of the apparent
Mr of the
U
S2 protein, whereas the
apparent
Mr of EHV-1 gD was reduced by
approximately 2 kDa after
de-O-glycosylation (data not
shown). From these experiments, we
concluded that the
U
S2 protein does not contain detectable N-
or O-linked
carbohydrates.
The EHV-1 US2 protein is membrane associated.
Two
approaches were taken to address the localization of the EHV-1
US2 protein. Firstly, viral envelopes were separated from nucleocapsids by incubation of purified RacL11 virions with 2% (final
concentration) Triton X-100 for 20 min at 45°C (31). The
resulting suspension was centrifuged for 30 min at 100,000 × g. The pellet containing viral nucleocapsids and the
supernatant (viral envelopes) were examined by Western blot analysis
using the US2-specific antiserum. Anti-EHV-1 gB monoclonal
antibody (MAb) 3F6 (2; kindly provided by G. P. Allen) and an IR6-specific antiserum which detects the
nucleocapsid-associated IR6 protein (31) were used to
control the prepared fractions. gB- and US2-specific reactivities were detected in lanes containing the Triton X-100-soluble proteins (Fig. 2B), whereas the IR6 protein localized to the
nucleocapsid fraction (Fig. 2B), as was demonstrated previously
(32). The reduced signal intensities of the detected viral
proteins in subviral fractions relative to whole virion lysates were
probably caused by the incubation at 45°C, because identical amounts
of lysates were loaded on the gel. Secondly, to investigate the
subcellular localization of the EHV-1 US2 protein, infected
cells were fractionated (4). Briefly, 107
Rk13 cells were infected with RacL11 at an MOI of 5 and
harvested at 14 h p.i. Cells were washed with PBS, scraped into
fractionation buffer (5 mM Na phosphate [pH 7.5], 2 mM
MgCl2, 0.5 mM CaCl2, 1 mM phenylmethylsulfonyl
fluoride), and broken with a Dounce homogenizer. After addition of
sucrose (final concentration, 0.3 M), still-intact cells, nuclei, and
large membrane fragments were pelleted (P-1) by low-speed
centrifugation (800 × g, 10 min). Supernatants were
collected and centrifuged (10 min, 10,000 × g) to
eliminate residual nuclei and cellular debris. The resulting supernatant was centrifuged (100,000 × g, 1 h,
4°C). The supernatant from this centrifugation step represented the
soluble components of the cytoplasm, whereas the pellet contained
plasma membrane fragments and vesicles from the endoplasmic reticulum
and Golgi network. To enrich infected-cell nuclei, P-1 was redissolved
in fractionation buffer containing 0.3 M sucrose and centrifuged twice
through a 1.62 M sucrose cushion (2,100 × g, 15 min).
The resulting pellet was dissolved in fractionation buffer containing 0.5% Triton X-100 and centrifuged for 15 min at 1,000 × g and contained mainly infected-cell nuclei.
All fractions were adjusted to the same protein concentration, and the
fractions

soluble cytoplasmic proteins and nuclear
and membrane
fractions

were subsequently analyzed by Western blotting.
MAb 3F6 and
the IR6-specific antiserum served as control antibodies
to confirm the
identities of the fractions. The anti-U
S2 antibody
specifically reacted with the 34,000-
Mr
U
S2 protein in membrane
and nuclear fractions only (Fig.
2C). The same subcellular distribution,
i.e., reactivity with
gB-specific bands in nuclear and membrane
fractions but not in the
soluble cytoplasmic fraction, was observed
with anti-gB MAb 3F6
(Fig.
2C). IR6-specific reactivity was not
detected in the membrane
fraction, whereas the 33,000-
Mr IR6 protein
was detected in the soluble cytoplasmic fraction and the nuclear
fraction, as reported previously (
32; data not
shown). Taken
together, these results indicated that the EHV-1
U
S2 protein is
associated with viral and cellular
membranes. Because the EHV-1
U
S2 protein could be
solubilized from pelleted membranes with
1% Triton X-100 and with 0.1 M Na
2CO
3 (pH 11.0) (
9), we concluded
that the EHV-1 U
S2 protein most likely represents a
peripheral
membrane protein (data not shown). To examine whether the
U
S2
protein is secreted from infected cells,
Rk
13 cells were grown
in medium without addition of fetal
calf serum and infected at
an MOI of 5 with wild-type strain RacL11. At
16 h p.i., the cell
culture supernatant was harvested and cleared
from cellular debris
and virions by ultracentrifugation, and the
protein concentration
was enriched by acetone precipitation. Western
blot analyses with
the U
S2-specific antiserum did not
detect U
S2 protein in the supernatant
of infected cells
(data not
shown).
Analysis of US2-GFP and hyUS2-GFP fusion
proteins.
Plasmids encoding fusion proteins consisting of GFP and
the full-length US2 protein or a US2 mutant
protein lacking the amino-terminal 20 amino acids containing a possible
transmembrane sequence (amino acids 1 to 16) (5, 26) were
constructed to monitor the intracellular trafficking of the
US2 protein. Full-length or truncated US2 genes were produced by PCR (39) (Table 1) and cloned into vector pEGFP-N1 (Clontech). The resulting plasmids, pUS2-GFP and
phyUS2-GFP (Fig. 1), were transfected into Rk13
cells seeded on coverslips (33, 34). At different times
posttransfection (p.tr.), cells were fixed with 3% paraformaldehyde in
PBS-0.3% Triton X-100. Nuclear DNA was stained with 10
6
M propidium iodide (PI), and indirect immunofluorescent staining using
an anti-
-adaptin MAb (Sigma) or anti-EHV-1 gB MAb 3F6 was done as
previously described (34). Coverslips were analyzed by using
a confocal laser scanning microscope (Zeiss LSM 510). Green (GFP) and
red (PI, Cy3) fluorescences were recorded separately by using
appropriate filters (34). Fluorescence signals were readily
detected in cells transfected with either plasmid starting at 8 h
p.tr. At 24 h p.tr., both the US2-GFP and
hyUS2-GFP fusion proteins accumulated in the vicinity of
nuclei and at the plasma membrane of transfected cells. Intranuclear
staining, however, was not observed (Fig.
3). The distribution of the fusion
proteins within transfected cells did not significantly change with
time, and at 48 h p.tr., the same pattern of fluorescence was
observed in cells transfected with either pUS2-GFP or
phyUS2-GFP. In pEGFP-N1-transfected cells, bright and
homogeneously distributed nuclear and cytoplasmic fluorescence was
observed at 24 h (Fig. 3) and also at 48 h p.tr. To examine
the possible presence of the GFP fusions in the secretory pathway of
transfected cells, colocalization studies using a
-adaptin antibody, a marker of the trans-Golgi network, were performed. Colocalization of US2-GFP or hyUS2-GFP
signals with
-adaptin was not observed at any time p.tr.
Similarly, colocalization of the GFP fusion proteins with gB was not
observed after infection of previously transfected cells with
RacL11 (data not shown).

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 3.
Confocal laser scanning image of Rk13 cells
transfected with pUS2-GFP (A), phyUS2-GFP (B),
or pEGFP-N1 alone (C). Cells were transfected with 5 µg of the
indicated plasmid and fixed at 24 h after transfection. Cellular
DNA was counterstained with 10 6 M PI. Green and red
fluorescences were recorded separately by using appropriate filters,
merged, and printed. Magnification, ×1,000.
|
|
Growth characteristics of US2-negative EHV-1 in
vitro.
The US2-negative EHV-1 mutant
L11
US2 was constructed (30, 33) by
cotransfection of 1 µg of RacL11 DNA and 10 µg of recombinant plasmid p
US2
+ (Fig. 1). Plasmid
p
US2
+ contains a 3.3-kbp PstI
fragment comprising the US-IRS junction, the
entire US2 gene, and flanking sequences of EHV-1
strain RacL11, in which the US2-coding sequences for
amino acids 12 to 221 were replaced with a
-galactosidase expression
cassette (29) (Fig. 1). After addition of Bluo-Gal
(Gibco-BRL), blue-staining virus plaques were picked and purified to
homogeneity. The repaired virus R-L11
US2 was isolated
after cotransfection of L11
US2 DNA and the 3.3-kbp
PstI fragment (Fig. 1) by purification of white virus
plaques in the presence of Bluo-Gal. Recombinant viruses were tested by
Southern blot analyses using a US2 probe and a lacZ probe (Fig. 1), and the expected genotypes of both
recombinant viruses were confirmed. Isolation of L11
US2
on noncomplementing Rk13 cells demonstrated that the
US2 gene is nonessential for virus replication in vitro. To
characterize the growth properties of L11
US2 in detail,
a series of experiments was performed. Growth kinetics of
the mutant virus after infection with different MOIs were
determined. Rk13 cells (106) were infected
at an MOI of 1, 0.1, or 0.01 with L11
US2, RacL11, or
R-L11
US2. At 24 h p.i., infectious virus
was harvested by freeze-thawing and titrated on Rk13 cells.
In all cases, L11
US2 grew to titers which were
comparable to those produced by RacL11 and R-L11
US2
(Fig. 4A). To determine single-step
growth kinetics, 106 Rk13 cells were infected
with the indicated viruses at an MOI of 5. After 1.5 h of
incubation at 37°C, extracellular viruses were inactivated with a
citrate buffer (pH 3.0) for 2 min (17). At different times
p.i., supernatants were harvested and virus titers were determined on
Rk13 cells. The results of the single-step growth
kinetics corroborated the findings reported above, and no
significant differences in the amount of infectious viruses produced
were observed among RacL11, L11
US2, or the repaired virus (Fig. 4B). Plaque sizes of L11
US2, however,
were slightly but significantly smaller than those observed in the case
of either RacL11 or R-L11
US2 (Fig. 4C). To test whether
the US2 gene plays a role in viral entry, virus
penetration assays were performed (17, 30). It could be
shown that whereas 50% of RacL11 or R-L11
US2
infectivity was protected from acid treatment at 35 min after a
temperature shift to 37°C, only 30% of L11
US2
infectivity was protected at this time point. After 2 h of
incubation at 37°C, approximately 90% of the input RacL11 and
R-L11
US2 viruses, but only 60% of L11
US2
virions, had entered the cells (Fig. 4D). It should be noted that virus
adsorption assays using purified virions labeled with
[methyl-3H]thymidine did not reveal
significant differences in adsorption kinetics between
L11
US2 and parental virus RacL11 or
R-L11
US2 (data not shown). From these experiments, it
was concluded that the US2 gene product modulates viral
penetration and cell-to-cell spread but does not influence virus
titers, even at a low MOI.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 4.
Analysis of US2-negative EHV-1 in vitro. (A)
Replication of RacL11, L11 US2, and
R-L11 US2 at different MOIs. Rk13 cells
(106) were infected at an MOI of 1, 0.1, or 0.01 and
treated for 2 min with citrate buffer (pH 3.0) at 2 h p.i.
(17). Viral titers were determined at 24 h p.i. The
values are means of three independent experiments, and standard
deviations (error bars) are given. (B) Single-step growth kinetics of
the different viruses. Rk13 cells (106) were
infected at an MOI of 5, and at the indicated times p.i., infected-cell
supernatants were harvested and titrated. The values are means and
standard deviations of three independent experiments. (C)
Rk13 cells seeded in six-well plates were infected with the
indicated viruses (200 PFU/well), and plaque sizes were determined. The
values are means of 150 individual plaques each. RacL11 plaque
diameters were set to 100%. Error bars indicate standard deviations.
(D) Penetration kinetics of RacL11, L11 US2, and
R-L11 US2 into Rk13 cells. The values are
means of four independent experiments. The error bars indicate standard
deviations.
|
|
Importance of the EHV-1 US2 protein in vivo.
To
analyze the influence of the US2 protein on EHV-1
virulence, experiments in a murine model of infection were performed (3, 19, 35). Three- to 4-week-old BALB/c mice (Charles River) were divided into groups of 14 and infected intranasally with
105 PFU (in 30 µl) of RacL11,
L11
US2, or R-L11
US2 virus per
mouse. Six control mice were inoculated with 30 µl of supernatant of uninfected Rk13 cells. The results are summarized as
follows (Fig. 5). (i) RacL11- and
R-L11
US2-infected mice lost approximately 30% of their
mean body weights until day 7 p.i., and three animals died as a
consequence of the infection. (ii) In contrast, none of the
L11
US2-infected mice died, although they also showed
typical signs of EHV-1 infection, such as ruffled fur and dyspnea from day 2 p.i. A decrease in mean body weight of up to 20% was
observed in this group. However, L11
US2-infected animals
recovered significantly faster than RacL11- and
R-L11
US2-infected mice and gained body weight from day
4 p.i. When pairwise testing of groups was done by the method of
Bonferroni (18), a significant difference between the groups
infected with RacL11 or R-L11
US2 and the animals
infected with L11
US2 could be demonstrated from days 4 to 8 p.i. Mock-infected animals did not show any signs of illness
and gradually gained weight during the duration of the experiment (Fig.
5A). Determination of viral titers of individual mice necropsied on
days 1 to 5 p.i. demonstrated that infected mice exhibited viral
titers of up to 107 per lung on day 1 p.i.,
irrespective of the inoculum. Therefore, viral replication
must have occurred, since only 105 PFU were
administered to each animal (Fig. 5B). Viral titers in lungs of
mice infected with L11
US2 were reduced on day 3 after infection compared to those of mice infected with RacL11
or R-L11
US2. On day 5 p.i., a 100-fold
decrease in virus titers was determined in lungs of
L11
US2-infected mice compared to mice infected with the
other viruses (Fig. 5B). In addition, blood was obtained by cardiac
puncture on day 3 p.i. and viremia could be detected in all
infected animals, although the viral load in the peripheral blood of
L11
US2-infected animals was approximately 50-fold lower than that of RacL11- or R-L11
US2-infected mice.
Virus could never be isolated from blood of mock-infected animals (data
not shown). From these data, we concluded that the EHV-1
US2 gene is nonessential for EHV-1 replication in vivo but
is required for a sustained virus load in murine lungs at later times
after infection.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 5.
Analysis of US2-negative EHV-1 in vivo. (A)
Fourteen BALB/c mice per group were infected with RacL11,
L11 US2, or R-L11 US2, and six mice were
mock infected. Body weights of individual mice were recorded daily from
the day of infection (day 0) until day 13 after infection, and mean
body weights on day 0 were set to 100%. Mean body weights (in relation
to day 0) and standard deviations (error bars) are shown. Decreasing
numbers of mice were weighed on days 0 and 1 (14), days 2 and 3 (12), days 4 and 5 (9), and days 6 to 13 (6). Two mice in the RacL11 group and one in the
R-L11 US2 group died. (B) Virus titers of the lungs
of two (days 1 and 5) or three (day 3) mice necropsied on day 1, 3, or
5 after infection. Mean virus titers and standard deviations
(error bars) are given.
|
|
Conclusions.
In this communication, an initial
characterization of the EHV-1 US2 protein is presented. The
salient findings are that the EHV-1 US2 protein (i) varies
in size between selected EHV-1 strains, (ii) predominantly
localizes to the membrane fraction of infected cells, (iii) is
present in the envelope fraction of purified virions, (iv) is
nonessential for virus growth in cultured cells but contributes to
virus penetration and efficient cell-to-cell spread, and (v) plays a role in sustained virus replication in vivo. Sequence analyses of selected EHV-1 strains had suggested that the size of the
EHV-1 US2 ORF is variable (5, 19, 43). It was
shown that strain Ab4 encodes a 44,000-Mr
US2 protein in infected cells, whereas another
wild-type EHV-1 strain, RacL11, encodes a
34,000-Mr US2 protein. The fact that
the Ab4 sequence determined here and that reported previously for
plaque-purified Ab4p (43) are identical indicates that the
frameshift mutation relative to wild-type strain RacL11 was not caused
by serial passage, as is the case for MLV strain RacH (19,
25). Mutations in both Ab4 and RacH are located in the
carboxy-terminal half of the molecule, which exhibits much less
homology within the subfamily Alphaherpesvirinae than does the amino-terminal portion (7, 26, 42, 43). Because no differences in the behavior of the different EHV-1 US2
proteins with regard to subcellular localization or virion
incorporation were observed, the functional domains appear to map to
the amino-terminal 224 amino acids of the US2 protein. The
EHV-1 US2 protein localized to the membrane fraction of
infected cells and the envelope fraction of purified virions. All
US2 homologs share a highly conserved stretch of 16 hydrophobic amino acids at the extreme amino terminus, and it was
suggested that the US2 homologs may encode a secreted or an
N-terminally anchored transmembrane (glyco)protein (5, 26).
However, several lines of evidence do not support the hypothesis that
the US2 protein is translated at membrane-bound ribosomes. Firstly, the US2 protein lacks carbohydrate modification.
Secondly, localization of the EHV-1 US2 protein to the
secretory pathway could not be demonstrated by using a
US2-GFP fusion protein and a marker of the trans-Golgi
network (
-adaptin). Thirdly, a fusion protein consisting of GFP and
US2 lacking the amino-terminal 20 amino acids of the
protein did not behave differently from US2-GFP after
transient expression: both fusion proteins were detectable at the
plasma membrane and appeared clustered around the nuclei of transfected
cells but did not exhibit the prominent granular appearance that is
typical of endoplasmic reticulum or Golgi vesicles. It should be noted
that the US2-GFP and hyUS2-GFP fusion proteins appeared in the same subcellular fractions as the native
US2 protein and were also present in the Triton
X-100-soluble fraction of purified virions after infection of
transfected cells with L11
US2. This was demonstrated by
Western blotting using the US2-specific antiserum and
anti-GFP antibodies (data not shown). So far, however, the exact
posttranslational processing and trafficking of the EHV-1
US2 protein is not entirely clear, and localization to the secretory pathway in infected cells cannot be formally excluded. We
were not able to visualize the native US2 protein in
infected cells because the antiserum did not react in indirect
immunofluorescence assays or immunoprecipitations. Therefore, GFP
fusions were used to monitor the intracellular trafficking of the
US2 protein. Previous reports on herpesviral proteins fused
to GFP have demonstrated that the properties of the viral proteins,
especially their subcellular localization, did not differ from those of
the native protein (6, 14).
Nevertheless, it is possible that the U
S2 protein needs
another viral protein for translocation to the secretory pathway,
although a disulfide-linked complex of the U
S2 protein with
a
viral or cellular partner is very unlikely, as concluded from
analyses using two-dimensional PAGE under nonreducing and reducing
conditions (
10,
20; data not shown). The HSV-1
U
S2-encoded
protein and the PrV and MDV homologs are
nonessential for virus
growth in vitro (
36,
37,
45).
Similarly, the EHV-1 U
S2 protein
is nonessential for virus
growth, but the U
S2-negative RacL11
mutant is slightly
impaired in virus penetration and cell-to-cell
spread. These findings
correlate well with the presence of the
U
S2 protein in the
membrane fraction of infected cells and in
the Triton X-100-soluble
fraction of purified virions. In addition,
restricted growth of
L11

U
S2 in infected animals at late times
p.i. was
observed. Despite these properties of U
S2-negative RacL11,
it is very unlikely that the alteration of the last 27 amino acids
of
the U
S2 protein of MLV strain RacH accounts for its
apathogenicity
because (i) RacH entirely lacks the direct neighbor of
U
S2, the
IR6 gene, which has been shown to be involved in
virulence (
33);
(ii) EHV-1 strains RacM24 and RacM36
expressing a wild-type U
S2
protein but carrying mutations
in the IR6 gene are completely
apathogenic (
19,
25); and
(iii) preliminary results indicate
that a RacH virus in which the
wild-type U
S2 gene has been inserted
is still
completely apathogenic for mice. In contrast to the effects
of the
deletion of the U
S2 gene reported here, HSV-1, PrV, and
MDV
mutants with deletions in the U
S2 homologous genes retain
their pathogenicity (
27,
36,
37,
45,
46). Whether these
differences are caused by distinct functions of the U
S2
proteins
in the context of both different viruses and different hosts
remains
to be
analyzed.
 |
ACKNOWLEDGMENTS |
We thank George P. Allen, University of Kentucky, Lexington, for
generously providing MAbs 3F6 and 20C4; Neil Edington, Royal Veterinary
College, London, United Kingdom, for EHV-1 strain Ab4; and Dennis J. O'Callaghan, LSUMC, Shreveport, La., for EHV-1 strain KyA and the
anti-IR6 serum.
A.M. was supported by a grant from the Studienstiftung des Deutschen
Volkes. Part of this study was financed by a grant from the
Mehl-Mülhens-Stiftung to N.O.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Institute of
Molecular and Cellular Virology, Friedrich-Loeffler-Institutes, Federal Research Center for Virus Diseases of Animals, D-17498 Insel Riems, Germany. Phone: 49-38351-7266. Fax: 49-38351-7151. E-mail:
klaus.osterrieder{at}rie.bfav.de.
 |
REFERENCES |
| 1.
|
Allen, G. P., and J. T. Bryans.
1986.
Molecular epizootiology, pathogenesis, and prophylaxis of equine herpesvirus-1 infections.
Prog. Vet. Microbiol. Immunol.
2:78-144[Medline].
|
| 2.
|
Allen, G. P., and M. R. Yeargan.
1987.
Use of gt11 and monoclonal antibodies to map the genes for the six major glycoproteins of equine herpesvirus 1.
J. Virol.
61:2454-2461[Abstract/Free Full Text].
|
| 3.
|
Awan, A. R.,
Y. C. Chong, and H. J. Field.
1990.
The pathogenesis of equine herpesvirus type 1 in the mouse: a new model for studying host responses to the infection.
J. Gen. Virol.
71:1131-1140[Abstract/Free Full Text].
|
| 4.
|
Bogner, E.,
M. Reschke,
B. Reis,
E. Reis,
W. Britt, and K. Radsak.
1992.
Recognition of compartmentalized intracellular analogs of glycoprotein H of human cytomegalovirus.
Arch. Virol.
126:67-80[Medline].
|
| 5.
|
Breeden, C. A.,
R. R. Yalamanchili,
C. F. Colle, and D. J. O'Callaghan.
1992.
Identification and transcriptional mapping of genes encoded at the IR/Us junction of equine herpesvirus type 1.
Virology
191:649-660[Medline].
|
| 6.
|
Brideau, A. D.,
B. W. Banfield, and L. W. Enquist.
1998.
The Us9 gene product of pseudorabies virus, an alphaherpesvirus, is a phosphorylated, tail-anchored type II membrane protein.
J. Virol.
72:4560-4570[Abstract/Free Full Text].
|
| 7.
|
Brunovskis, P., and L. F. Velicer.
1995.
The Marek's disease virus (MDV) unique short region: alphaherpesvirus-homologous, fowlpox virus-homologous, and MDV-specific genes.
Virology
206:324-338[Medline].
|
| 8.
|
Cantello, J. L.,
A. S. Anderson,
A. Francesconi, and R. W. Morgan.
1991.
Isolation of a Marek's disease virus (MDV) recombinant containing the lacZ gene of Escherichia coli stably inserted within the MDV US2 gene.
J. Virol.
65:1584-1588[Abstract/Free Full Text].
|
| 9.
|
Cockrell, A. S., and M. I. Muggeridge.
1998.
Herpes simplex virus 2 UL45 is a type II membrane protein.
J. Virol.
72:4430-4433[Abstract/Free Full Text].
|
| 10.
|
Cohen, G. H.,
V. J. Isola,
J. Kuhns,
P. W. Berman, and R. J. Eisenberg.
1986.
Localization of discontinuous epitopes of herpes simplex virus glycoprotein D: use of a nondenaturing ("native" gel) system of polyacrylamide gel electrophoresis coupled with Western blotting.
J. Virol.
60:157-166[Abstract/Free Full Text].
|
| 11.
|
Colle, C. F., and D. J. O'Callaghan.
1995.
Transcriptional analyses of the unique short segment of EHV-1 strain Kentucky A.
Virus Genes
9:257-268[Medline].
|
| 12.
|
Davison, A. J.
1983.
DNA sequence of the US component of the varicella-zoster virus genome.
EMBO J.
2:2203-2209[Medline].
|
| 13.
|
Dolan, A.,
F. E. Jamieson,
C. Cunningham,
B. C. Barnett, and D. J. McGeoch.
1998.
The genome sequence of herpes simplex virus type 2.
J. Virol.
72:2010-2021[Abstract/Free Full Text].
|
| 14.
|
Elliott, G., and P. O'Hare.
1997.
Intercellular trafficking and protein delivery by a herpesvirus structural protein.
Cell
88:223-233[Medline].
|
| 15.
|
Haanes, E. J., and C. C. Tomlinson.
1998.
Genomic organization of the canine herpesvirus US region.
Virus Res.
53:151-162[Medline].
|
| 16.
|
Henry, B. E.,
R. A. Robinson,
S. A. Dauenhauer,
S. S. Atherton,
G. S. Hayward, and D. J. O'Callaghan.
1981.
Structure of the genome of equine herpesvirus type 1.
Virology
115:97-114[Medline].
|
| 17.
|
Highlander, S. L.,
W. Cai,
S. Person,
M. Levine, and J. C. Glorioso.
1988.
Monoclonal antibodies define a domain on herpes simplex virus glycoprotein B involved in virus penetration.
J. Virol.
62:1881-1888[Abstract/Free Full Text].
|
| 18.
|
Holm, S.
1979.
A simple sequentially rejective multiple test procedure.
Scand. J. Stat.
6:65-70.
|
| 19.
|
Hübert, P. H.,
S. Birkenmaier,
H. J. Rziha, and N. Osterrieder.
1996.
Alterations in the equine herpesvirus type-1 (EHV-1) strain RacH during attenuation.
J. Vet. Med. B
43:1-14.
|
| 20.
|
Jöns, A.,
J. M. Dijkstra, and T. C. Mettenleiter.
1998.
Glycoproteins M and N of pseudorabies virus form a disulfide-linked complex.
J. Virol.
72:550-557[Abstract/Free Full Text].
|
| 21.
|
Kimman, T. G.,
N. DeWind,
N. Oei-Lie,
J. M. A. Pol,
A. J. M. Berns, and A. L. J. Gielkens.
1992.
Contribution of single genes within the unique short of Aujeszky's disease virus (Suid herpesvirus type 1) to virulence, pathogenesis and immunogenicity.
J. Gen. Virol.
73:243-251[Abstract/Free Full Text].
|
| 22.
|
Kyhse-Andersen, J.
1984.
Electroblotting of multiple gels: a simple apparatus without tank for rapid transfer of proteins from polyacrylamide gels to nitrocellulose.
J. Biochem. Biophys. Methods
10:203-210[Medline].
|
| 23.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:680-685[Medline].
|
| 24.
|
Leung-Tack, P.,
J. C. Audonnet, and M. Riviere.
1994.
The complete DNA sequence and the genetic organization of the short unique region (US) of the bovine herpesvirus type 1 (ST strain).
Virology
199:409-421[Medline].
|
| 25.
|
Mayr, A.,
J. Pette,
K. Petzoldt, and K. Wagener.
1968.
Untersuchungen zur Entwicklung eines Lebendimpfstoffes gegen die Rhinopneumonitis (Stutenabort) der Pferde.
J. Vet. Med. B
15:406-418.
|
| 26.
|
McGeoch, D. J.
1985.
On the predictive recognition of signal peptide sequences.
Virus Res.
3:271-286[Medline].
|
| 27.
|
Meignier, B.,
R. Longnecker,
P. Mavromara Nazos,
A. E. Sears, and B. Roizman.
1988.
Virulence of and establishment of latency by genetically engineered deletion mutants of herpes simplex virus 1.
Virology
162:251-254[Medline].
|
| 28.
|
Mettenleiter, T. C.,
B. Lomniczi,
N. Sugg,
C. Schreurs, and T. Ben-Porat.
1988.
Host cell-specific growth advantage of pseudorabies virus with a deletion in the genome sequences encoding a structural glycoprotein.
J. Virol.
62:12-19[Abstract/Free Full Text].
|
| 29.
|
Mettenleiter, T. C., and I. Rauh.
1990.
A glycoprotein gX- -galactosidase fusion gene as insertional marker for rapid identification of pseudorabies virus mutants.
J. Virol. Methods
30:55-66[Medline].
|
| 30.
|
Neubauer, A.,
B. Braun,
C. Brandmüller,
O. R. Kaaden, and N. Osterrieder.
1997.
Analysis of the contributions of the equine herpesvirus 1 glycoprotein gB homolog to virus entry and direct cell to cell spread.
Virology
227:281-294[Medline].
|
| 31.
|
O'Callaghan, D. J.,
C. F. Colle,
C. C. Flowers,
R. H. Smith,
J. N. Benoit, and C. A. Bigger.
1994.
Identification and initial characterization of the IR6 protein of equine herpesvirus 1.
J. Virol.
68:5351-5364[Abstract/Free Full Text].
|
| 32.
|
Osterrieder, N.,
V. R. Holden,
C. Brandmüller,
A. Neubauer,
O. R. Kaaden, and D. J. O'Callaghan.
1996.
The equine herpesvirus 1 IR6 protein is nonessential for virus growth in vitro and modified by serial virus passage in cell culture.
Virology
217:442-451[Medline].
|
| 33.
|
Osterrieder, N.,
A. Neubauer,
C. Brandmüller,
O. R. Kaaden, and D. J. O'Callaghan.
1996.
The equine herpesvirus 1 IR6 protein influences virus growth at elevated temperature and is a major determinant of virulence.
Virology
226:243-251[Medline].
|
| 34.
|
Osterrieder, N.,
A. Neubauer,
C. Brandmüller,
O.-R. Kaaden, and D. J. O'Callaghan.
1998.
Equine herpesvirus 1 IR6 protein that colocalizes with nuclear lamins is involved in nucleocapsid egress and migrates from cell to cell independently of virus infection.
J. Virol.
72:9806-9817[Abstract/Free Full Text].
|
| 35.
|
Osterrieder, N.,
R. Wagner,
C. Brandmüller,
P. Schmidt,
H. Wolf, and O. R. Kaaden.
1995.
Protection against EHV-1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB).
Virology
208:500-510[Medline].
|
| 36.
|
Parcells, M. S.,
A. S. Anderson,
J. L. Cantello, and R. W. Morgan.
1994.
Characterization of Marek's disease virus insertion and deletion mutants that lack US1 (ICP22 homolog), US10, and/or US2 and neighboring short-component open reading frames.
J. Virol.
68:8239-8253[Abstract/Free Full Text].
|
| 37.
|
Parcells, M. S.,
A. S. Anderson, and T. W. Morgan.
1995.
Retention of oncogenicity by a Marek's disease virus mutant lacking six unique short region genes.
J. Virol.
69:7888-7898[Abstract].
|
| 38.
|
Petrovskis, E. A., and L. E. Post.
1987.
A small open reading frame in pseudorabies virus and implications for evolutionary relationships between herpesviruses.
Virology
159:193-195[Medline].
|
| 39.
|
Saiki, A. K.,
D. H. Gelfand,
S. Stoffel,
S. Scharf,
R. Higuchi,
G. T. Horn,
K. B. Mullis, and H. A. Ehrlich.
1988.
Primer directed enzymatic amplification of DNA with a thermostable DNA polymerase.
Science
239:487-491[Abstract/Free Full Text].
|
| 40.
|
Sakaguchi, M.,
T. Urakawa,
Y. Hirayama,
N. Miki,
M. Yamamoto, and K. Hirai.
1992.
Sequence determination and genetic content of an 8.9-kb restriction fragment in the short unique region and the internal inverted repeat of Marek's disease virus type 1 DNA.
Virus Genes
6:365-378[Medline].
|
| 41.
|
Sambrook, J.,
D. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 42.
|
Telford, E. A.,
M. S. Watson,
J. Perry,
A. A. Cullinane, and A. J. Davison.
1998.
The DNA sequence of equine herpesvirus-4.
J. Gen. Virol.
79:1197-1203[Abstract].
|
| 43.
|
Telford, E. A.,
M. S. Watson,
K. McBride, and A. J. Davison.
1992.
The DNA sequence of equine herpesvirus-1.
Virology
189:304-316[Medline].
|
| 44.
|
van Zijl, M.,
H. van der Gulden,
N. de Wind,
A. Gielkens, and A. Berns.
1990.
Identification of two genes in the unique short region of pseudorabies virus: comparison with herpes simplex virus and varicella-zoster virus.
J. Gen. Virol.
71:1747-1755[Abstract/Free Full Text].
|
| 45.
|
Wagenaar, F.,
J. M. A. Pol,
B. Peeters,
A. L. J. Gielkens,
N. DeWind, and T. G. Kimman.
1995.
The US3 encoded protein kinase from pseudorabies virus affects egress of virions from the nucleus.
J. Gen. Virol.
76:1851-1859[Abstract/Free Full Text].
|
| 46.
|
Weber, P. C.,
M. Levine, and J. C. Glorioso.
1987.
Rapid identification of nonessential genes of herpes simplex virus type 1 by Tn5 mutagenesis.
Science
236:576-579[Abstract/Free Full Text].
|
| 47.
|
Whalley, J. M.,
G. R. Robertson, and A. J. Davison.
1981.
Analysis of the genome of equine herpesvirus type 1: arrangement of cleavage sites for restriction endonucleases EcoRI, BglII and BamHI.
J. Gen. Virol.
57:307-323[Abstract/Free Full Text].
|
| 48.
|
Wild, M. A.,
S. Cook, and M. Cochran.
1996.
A genomic map of infectious laryngotracheitis virus and the sequence and organization of genes present in the unique short and flanking regions.
Virus Genes
12:107-116[Medline].
|
| 49.
|
Zelnik, V.,
R. Darteil,
J. C. Audonnet,
G. D. Smith,
M. Riviere,
J. Pastorek, and L. J. Ross.
1993.
The complete sequence and gene organization of the short unique region of herpesvirus of turkeys.
J. Gen. Virol.
74:2151-2162[Abstract/Free Full Text].
|
Journal of Virology, April 1999, p. 3430-3437, Vol. 73, No. 4
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Jarosinski, K. W., Margulis, N. G., Kamil, J. P., Spatz, S. J., Nair, V. K., Osterrieder, N.
(2007). Horizontal Transmission of Marek's Disease Virus Requires US2, the UL13 Protein Kinase, and gC. J. Virol.
81: 10575-10587
[Abstract]
[Full Text]
-
Lyman, M. G., Randall, J. A., Calton, C. M., Banfield, B. W.
(2006). Localization of ERK/MAP Kinase Is Regulated by the Alphaherpesvirus Tegument Protein Us2. J. Virol.
80: 7159-7168
[Abstract]
[Full Text]
-
Nugent, J., Birch-Machin, I., Smith, K. C., Mumford, J. A., Swann, Z., Newton, J. R., Bowden, R. J., Allen, G. P., Davis-Poynter, N.
(2006). Analysis of Equid Herpesvirus 1 Strain Variation Reveals a Point Mutation of the DNA Polymerase Strongly Associated with Neuropathogenic versus Nonneuropathogenic Disease Outbreaks.. J. Virol.
80: 4047-4060
[Abstract]
[Full Text]
-
Schumacher, D., Tischer, B. K., Trapp, S., Osterrieder, N.
(2005). The Protein Encoded by the US3 Orthologue of Marek's Disease Virus Is Required for Efficient De-Envelopment of Perinuclear Virions and Involved in Actin Stress Fiber Breakdown. J. Virol.
79: 3987-3997
[Abstract]
[Full Text]
-
Clase, A. C., Lyman, M. G., del Rio, T., Randall, J. A., Calton, C. M., Enquist, L. W., Banfield, B. W.
(2003). The Pseudorabies Virus Us2 Protein, a Virion Tegument Component, Is Prenylated in Infected Cells. J. Virol.
77: 12285-12298
[Abstract]
[Full Text]
-
Rudolph, J., Seyboldt, C., Granzow, H., Osterrieder, N.
(2002). The Gene 10 (UL49.5) Product of Equine Herpesvirus 1 Is Necessary and Sufficient for Functional Processing of Glycoprotein M. J. Virol.
76: 2952-2963
[Abstract]
[Full Text]
-
Ohsawa, K., Black, D. H., Sato, H., Eberle, R.
(2002). Sequence and Genetic Arrangement of the US Region of the Monkey B Virus (Cercopithecine Herpesvirus 1) Genome and Comparison with the US Regions of Other Primate Herpesviruses. J. Virol.
76: 1516-1520
[Abstract]
[Full Text]
-
Schumacher, D., Tischer, B. K., Reddy, S. M., Osterrieder, N.
(2001). Glycoproteins E and I of Marek's Disease Virus Serotype 1 Are Essential for Virus Growth in Cultured Cells. J. Virol.
75: 11307-11318
[Abstract]
[Full Text]
-
Schumacher, D., Tischer, B. K., Fuchs, W., Osterrieder, N.
(2000). Reconstitution of Marek's Disease Virus Serotype 1 (MDV-1) from DNA Cloned as a Bacterial Artificial Chromosome and Characterization of a Glycoprotein B-Negative MDV-1 Mutant. J. Virol.
74: 11088-11098
[Abstract]
[Full Text]